Shares of Jagsonpal Pharmaceuticals rose sharply after the company announced that its board will meet on March 12 to consider a proposal to buy back its equity shares. If approved, this would be the company’s first share buyback since it was listed.
The proposed buyback will involve fully paid equity shares with a face value of ₹2 each. Investors reacted positively to the announcement, pushing the company’s stock higher during trading as markets viewed the move as a sign of confidence from management.
A share buyback allows a company to repurchase its own shares from the market. This usually reduces the number of shares available publicly and can increase shareholder value by improving earnings per share. Companies often use buybacks when they believe their stock is undervalued.
The company has undertaken several corporate actions in the past. It issued bonus shares in a 3:1 ratio in 2004 and recently carried out a stock split in January 2025, reducing the face value of shares from ₹5 to ₹2. The company has also maintained regular dividend payouts.
In its latest financial results for the December 2025 quarter, the company reported a slight dip in performance. Net profit declined 8.4% to ₹12.49 crore, while revenue from operations fell 1.5% to ₹72.95 crore compared with the same period a year earlier.
Jagsonpal Pharmaceuticals is known for its presence in therapeutic segments such as gynaecology, orthopaedics, dermatology and paediatric medicines. According to the latest shareholding data, promoters held over 67% stake in the company as of December 2025.
Also Read: Strategy expands Bitcoin holdings with major purchase